Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent

J A Sakoff1, S P Ackland

  • 1Department of Medical Oncology, Newcastle Mater Misericordiae Hospital, Newcastle, NSW, Australia, 2298. mdspa8@cc.newcastle.edu.au

Insights

Thymidylate synthase (TS) inhibition triggers apoptosis and mitochondrial changes in leukemia cells. Caspase involvement in cell death pathways differs between L1210 and HL60 cell lines following TS inhibition.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Thymidylate synthase (TS) is a critical enzyme in DNA synthesis.
  • Inhibition of TS is a common strategy in cancer chemotherapy.
  • Understanding downstream effects of TS inhibition is crucial for optimizing cancer treatment.

Purpose of the Study:

  • To investigate the downstream effects of TS inhibition on L1210 and HL60 leukemia cells.
  • To elucidate the role of mitochondrial membrane potential and caspases in TS inhibition-induced cell death.

Main Methods:

  • TS inhibition induced using Thymitaq.
  • Cell cycle analysis (S-phase arrest).
  • Apoptosis assessment (nuclear condensation, DNA fragmentation, apoptotic bodies).
  • Mitochondrial membrane potential (Δψm) analysis.
  • Pharmacological inhibition of caspases (zVAD.fmk) and mitochondrial permeability transition (cyclosporin A, bongkrekic acid).

Main Results:

  • TS inhibition caused S-phase arrest and apoptosis in both cell lines within 24 hours.
  • A biphasic alteration in mitochondrial membrane potential (Δψm) was observed.
  • Caspase inhibition (zVAD.fmk) affected Δψm and apoptosis differently in L1210 and HL60 cells.
  • Caspases acted as downstream effectors of apoptosis in L1210 cells but not in HL60 cells.

Conclusions:

  • TS inhibition induces apoptosis via a pathway involving biphasic Δψm alterations.
  • Caspase-dependent apoptosis occurs downstream of mitochondrial events in L1210 cells.
  • HL60 cells exhibit caspase-independent or alternative cell death mechanisms following TS inhibition.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...